There is a slight risk associated with trading before and after the market open. Due to lower liquidity and higher volatility, extended-hours trading may result in wider spreads on particular security due to the release of critical financial information after regular trading hours. After-hours trades for Cronos Group Inc. (CRON) shows that investor sentiment remained broken, with the stock’s consolidated last price falling by -$0.02, or -1.07%, to $1.85. The Cronos Group Inc. has recorded 8,357 volume in the after hours trading session. Yahoo Finance discussed the stock recently as it posted Cronos Group Inc. to Hold Virtual 2023 Annual Meeting of Shareholders.
Unlock the Hottest Top 10 Penny Stocks Today! Discover Now
Dive into the world of lucrative penny stocks with MarketClub's groundbreaking "Smart Scan" technology! Get an instant snapshot of the top 50 high volume stocks with a clear direction and outstanding liquidity - in other words, the strongest trending. To unlock this exclusive list, simply provide your first name, last name, and email for instant access.
Gain Access to Top 10 Penny Stocks Now!.
This NASDAQ-listed company operates within the Drug Manufacturers – Specialty & Generic industry segment, falling under the Healthcare sector. At the end of the last regular session, the stock closed at $1.87 and fluctuated between $1.8900 as its day high and $1.8200 as its day low. The current market capitalization of Cronos Group Inc. is $952.80M. A total of 1.07 million shares were traded on the day, compared to an average of 1.68M shares.
In the most recent transaction, ADLER JASON MARC bought 109,588 shares of CRON for 2.81 per share on Dec 15. After the transaction, the Director now owns 1,049,988 company shares. In a previous transaction on Dec 14, ADLER JASON MARC bought 94,600 shares at 2.83 per share. CRON shares that Director owns now total 973,277.
Among the insiders who bought shares, ADLER JASON MARC acquired of 88,152 shares on Dec 13 at a per-share price of $2.89. This resulted in the Director holding 907,058 shares of CRON after the transaction. In another insider transaction, ADLER JASON MARC bought 86,000 shares at $2.90 per share on Dec 12. Company shares held by the Director now total 845,352.
Even though price targets are rarely accurate, they do tend to exert some kind of influence from time to time and are often considered important by markets. According to analysts who have offered 12-month price targets for CRON in the last 3 months, the mean price target is $2.55 with high estimates of $3.12 and low estimates of $2.10. In terms of 52-week highs and lows, CRON has a high of $3.62 and a low of $1.70.
As of this writing, CRON has an earnings estimate of -$0.05 per share for the current quarter. EPS was calculated based on a consensus of 4 estimates, with a high estimate of -$0.02 per share and a lower estimate of -$0.07. The company reported an EPS of -$0.1 in the last quarter, which was -66.70% lower than expectations of -$0.06.
Balance Sheet Annually/Quarterly
In a balance sheet, you can see what assets and liabilities the company has, as well as how much equity investors have invested. These figures can be used to calculate a company’s financial ratios to give investors a better idea of its prospects. CRON’s latest balance sheet shows that the firm has $1.00B in Cash & Short Term Investments as of fiscal 2021. There were $9.81M in debt and $54.37M in liabilities at the time. Its Book Value Per Share was $4.11, while its Total Shareholder’s Equity was $1.33B.
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 10 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CRON is Hold with a score of 3.50. A total of 2 analysts rated the stock as Buy while 2 rated it as Overweight while 5 rated it as Hold. Among the other participants, 1 thought the stock was Underweight and 0 thought it should be Sold.